Mood disorders are mental health conditions that involve changes in a person’s mood that cause distress and disruption in their day-to-day life, such as feelings of sadness, anxiety, mania, or hopelessness. They can include symptoms like hopelessness, loss of interest in activities, sleep problems, cognitive difficulties, and thoughts of suicide or self-harm. While mood disorders can affect people of any age or gender, they are more common in adults. The two most common types of mood disorders are major depressive disorder (MDD) and bipolar disorder. MDD is characterized by significant feelings of sadness, loss of interest in activities, insomnia, low energy, and anxiety. Symptoms of bipolar disorder alternate between periods of depression and mania, with manic episodes including symptoms such as excessive talking, lack of focus, euphoria, and irritability. Mood disorders can have a range of potential causes, including biological, psychological, and environmental factors. In some cases, mood disorders may be related to genetics and physical changes in the brain. Environmental factors such as stress, trauma, substance abuse, and life changes can also contribute to mood disorders. The exact cause of each disorder is not yet known, so diagnosis and treatment can vary widely. Treatment for mood disorders typically involves a combination of pharmacological and psychotherapeutic approaches. Medications such as antidepressants and mood stabilizers are used to help modify symptoms of the disorder. Additionally, psychotherapy focuses on understanding and addressing the underlying causes of the disorder, helping the individual to better manage symptoms.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States